According to a recent LinkedIn post from Hemanext, the company has received U.S. FDA 510(k) clearance for expanded indications of its Hemanext ONE® system. The clearance reportedly allows processing of AS-3 leukocyte-reduced red blood cells from whole blood or apheresis collections within 72 hours of collection.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests this extended processing window could make it easier for blood centers to incorporate hypoxic RBC processing into existing workflows. If uptake materializes, this may support broader commercial adoption, potentially increasing recurring revenues tied to blood processing volumes.
Hemanext’s focus on hypoxic RBC quality and transfusion care positions it in a specialized segment of the transfusion medicine market. The company’s presence at America’s Blood Centers’ Annual Meeting in Tucson may help drive awareness and customer engagement, which could translate into additional pilot programs or contracts over time.
For investors, the new clearance may reduce a key operational barrier for customers by improving logistical flexibility in blood handling. While financial impact will depend on execution, contracting, and reimbursement dynamics, the development could strengthen Hemanext’s competitive position versus traditional storage methods and emerging rivals in blood processing technologies.